EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieOpen Access · CC BY-NC 4.0

Acute Dissociation and Ketamine’s Antidepressant and Anti-Suicidal Ideation Effects in a Midazolam-Controlled Trial

Sumra Sajid, Hanga C Galfalvy, John G Keilp, Ainsley K Burke, J John Mann, Michael F Grunebaum

International Journal of Neuropsychopharmacology · 2024

DOI: 10.1093/ijnp/pyae017 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift International Journal of Neuropsychopharmacology, 2024. Verfasst von Sumra Sajid und 5 weiteren Autor:innen. Beteiligte Einrichtung: New York State Psychiatric Institute, New York, New York, USA. Hauptthemen laut MEDLINE: Ketamine, Suicidal Ideation, Midazolam, Antidepressive Agents. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 55 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

We sought to explore relationships of acute dissociative effects of intravenous ketamine with change in depression and suicidal ideation and with plasma metabolite levels in a randomized, midazolam-controlled trial.

Methods

Data from a completed trial in suicidal, depressed participants (n = 40) randomly assigned to ketamine was used to examine relationships between ketamine treatment–emergent dissociative and psychotomimetic symptoms with pre/post-infusion changes in suicidal ideation and depression severity. Nonparametric correlational statistics were used. These methods were also used to explore associations between dissociative or psychotomimetic symptoms and blood levels of ketamine and metabolites in a subset of participants (n = 28) who provided blood samples immediately post-infusion.

Results

Neither acute dissociative nor psychotomimetic effects of ketamine were associated with changes in suicidal ideation or depressive symptoms from pre- to post-infusion. Norketamine had a trend-level, moderate inverse correlation with dissociative symptoms on Day 1 post-injection (P = .064; P =.013 removing 1 outlier). Dehydronorketamine correlated with Clinician-Administered Dissociative States Scale scores at 40 minutes (P = .034), 230 minutes (P = .014), and Day 1 (P = .012).

Conclusion

We did not find evidence that ketamine’s acute, transient dissociative, or psychotomimetic effects are associated with its antidepressant or anti-suicidal ideation actions. The correlation of higher plasma norketamine with lower dissociative symptoms on Day 1 post-treatment suggests dissociation may be more an effect of the parent drug.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

KetamineSuicidal IdeationMidazolamAntidepressive AgentsDissociative DisordersHumansMaleAdultFemaleMiddle AgedYoung AdultDouble-Blind Method

Stichwörter der Autor:innen

Ketaminedepressiondissociationplasma metabolitesuicidal ideation

Substanzen

KetamineMidazolamAntidepressive Agentsnorketamine

Autor:innen und Institutionen

  • New York State Psychiatric Institute, New York, New York, USA.
  • Columbia University Irving Medical Center and New York State Psychiatric Institute, New York, New York, USA.

Zitieren

APA

Sajid, S., Galfalvy, H. C., Keilp, J. G., Burke, A. K., Mann, J. J., & Grunebaum, M. F. (2024). Acute Dissociation and Ketamine’s Antidepressant and Anti-Suicidal Ideation Effects in a Midazolam-Controlled Trial. International Journal of Neuropsychopharmacology. https://doi.org/10.1093/ijnp/pyae017

Vancouver

Sajid S, Galfalvy HC, Keilp JG, Burke AK, Mann JJ, Grunebaum MF. Acute Dissociation and Ketamine’s Antidepressant and Anti-Suicidal Ideation Effects in a Midazolam-Controlled Trial. International Journal of Neuropsychopharmacology. 2024. doi:10.1093/ijnp/pyae017

BibTeX
@article{Sajid2024,
  author = {Sajid, Sumra and Galfalvy, Hanga C and Keilp, John G and Burke, Ainsley K and Mann, J John and Grunebaum, Michael F},
  title = {Acute Dissociation and Ketamine’s Antidepressant and Anti-Suicidal Ideation Effects in a Midazolam-Controlled Trial},
  journal = {International Journal of Neuropsychopharmacology},
  year = {2024},
  doi = {10.1093/ijnp/pyae017}
}
Kostenlos starten →